Summary: In a predominantly Chinese population with type 2 diabetes inadequately controlled on metformin (n=1441), once-daily oral semaglutide at 3 mg, 7 mg and 14 mg produced significantly greater reductions in HbA1c and body weight than sitagliptin 100 mg over 26 weeks. Estimated treatment differences in HbA1c reached -11 mmol/mol (-1.0 percentage points) and in weight -3.3 kg at the highest dose, with a dose-dependent excess of gastrointestinal adverse events and treatment discontinuation.
PICO Summary
| Element | Detail |
|---|---|
| Population | 1441 adults with type 2 diabetes inadequately controlled on metformin (HbA1c 53-91 mmol/mol); randomised, double-dummy, double-blind Phase IIIa trial across 90 sites in the China region (mainland China, Taiwan, Hong Kong) and five other countries; 75.2% from the China region. |
| Intervention | Once-daily oral semaglutide 3 mg (n=361), 7 mg (n=360) or 14 mg (n=361) for 26 weeks. |
| Comparison | Once-daily oral sitagliptin 100 mg (n=359) for 26 weeks. |
| Outcome | Primary endpoint, change in HbA1c at week 26 (estimated treatment difference vs sitagliptin): 3 mg -2 mmol/mol (95% CI -4, -1) / -0.2 percentage points (-0.3, -0.1); 7 mg -8 mmol/mol (-9, -6) / -0.7 (-0.8, -0.6); 14 mg -11 mmol/mol (-12, -9) / -1.0 (-1.1, -0.8); all significant. Confirmatory secondary endpoint, body weight: -0.9 kg (-1.4, -0.4), -2.3 kg (-2.8, -1.8) and -3.3 kg (-3.8, -2.8) for 3, 7 and 14 mg; all significant. Premature treatment discontinuation 8.3%, 8.6% and 15.0% for semaglutide 3, 7 and 14 mg vs 4.2% for sitagliptin. Gastrointestinal events were the most frequent adverse events with semaglutide and were mostly transient and mild to moderate. No ARR/NNT reported (continuous endpoints). |
PIONEER 12: Oral Semaglutide vs Sitagliptin
RCT · type 2 diabetes · 26 weeks
All three doses of oral semaglutide cut HbA1c and weight more than sitagliptin, with dose-dependent gastrointestinal effects and higher discontinuation at 14 mg.
Expert Commentary
This double-blind, double-dummy Phase IIIa trial demonstrates dose-dependent superiority of oral semaglutide over sitagliptin for both glycaemic control and weight in a population in which East Asian patients have historically been under-represented in incretin trials. The verdict is that the primary and confirmatory secondary endpoints were met convincingly: the 14 mg dose lowered HbA1c by roughly one additional percentage point and reduced weight by a further 3.3 kg relative to an active comparator, and effects in the China-region subgroup mirrored the overall result. The masked, double-dummy design and active-comparator structure lend the findings credibility, and the effect sizes are biologically plausible rather than implausibly large. The principal limitation deserving weight is the tolerability and adherence trade-off: treatment discontinuation rose with dose to 15.0% at 14 mg, more than threefold the 4.2% seen with sitagliptin, driven largely by gastrointestinal effects, so the headline efficacy must be read alongside a meaningful real-world dropout signal. The trial was funded by Novo Nordisk, the manufacturer, and several authors are employees, which warrants the usual caution. Can I use this with my patients? Yes, for an adult with type 2 diabetes inadequately controlled on metformin who would benefit from added weight loss and prefers an oral agent, with explicit counselling on gastrointestinal effects and gradual titration. Outcomes beyond 26 weeks and on cardiovascular or renal endpoints were not assessed here and should anchor longer-term decisions.
References
Ji L, Agesen RM, Bain SC, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024;67(9):1800-1816. doi:10.1007/s00125-024-06133-4